Inventor · disambiguated record
Ann Dak-Yee Kwong
Also filed as: KWONG ANN · KWONG ANN D · KWONG ANN DAK-YEE
14 granted patents·11 pending applications·230 citations·filing 1998–2022
93Inventor score
Files withVERTEX PHARMA15KWONG ANN4DEWPOINT THERAPEUTICS INC2BARTELS DOUGLAS JOHN1KWONG ANN DAK-YEE1
Top patents by PatentIndex Score
25 records- 0196US9518056B2Inhibitors of influenza viruses replicationVERTEX PHARMA·Filed 2015·Granted Dec 13, 2016·16 cites·4 claims
- 0295US8829007B2Inhibitors of influenza viruses replicationVERTEX PHARMA·Filed 2013·Granted Sep 9, 2014·28 cites·2 claims
- 0394US9808459B2Inhibitors of influenza viruses replicationVERTEX PHARMA·Filed 2016·Granted Nov 7, 2017·11 cites·8 claims
- 0494US9345708B2Inhibitors of influenza viruses replicationVERTEX PHARMA·Filed 2014·Granted May 24, 2016·21 cites·16 claims
- 0592US10039762B2Inhibitors of influenza viruses replicationVERTEX PHARMA·Filed 2017·Granted Aug 7, 2018·7 cites·2 claims
- 0688US6528276B1Fusion proteins, DNA molecules, vectors, and host cells useful for measuring protease activityVERTEX PHARMA·Filed 2000·Granted Mar 4, 2003·29 cites·15 claims
- 0785US6117639AFusion proteins, DNA molecules, vectors, and host cells useful for measuring protease activityVERTEX PHARMA·Filed 1998·Granted Sep 12, 2000·110 cites·13 claims
- 0881US7705138B2Hepatitis C virus variantsVERTEX PHARMA·Filed 2006·Granted Apr 27, 2010·5 cites·28 claims
- 0972US8211696B2Method useful for HCV RNA898 infectionKWONG ANN·Filed 2011·Granted Jul 3, 2012·1 cites·12 claims
- 1070US7879606B2Compositions and methods useful for HCV infectionVERTEX PHARMA·Filed 2002·Granted Feb 1, 2011·1 cites·15 claims
- 1168US10874673B2Inhibitors of influenza viruses replicationVERTEX PHARMA·Filed 2018·Granted Dec 29, 2020·0 cites·30 claims
- 1267US8258116B2Combination therapy for the treatment of HCV infectionKWONG ANN·Filed 2008·Granted Sep 4, 2012·1 cites·15 claims
- 1358US2003083467A1Fusion proteins, DNA molecules, vectors, and host cells useful for measuring protease activityFiled 2002·Application pending·0 cites
- 1457US2024145034A1Methods of identifying a condensate phenotype and uses thereofDEWPOINT THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1555US2013344476A1Hepatitis c virus variantsVERTEX PHARMA·Filed 2013·Application pending·0 cites
- 1654US2014199684A1Methods for amplifying hepatitis c virus nucleic acidsVERTEX PHARMA·Filed 2014·Application pending·0 cites
- 1754US2013071834A1Compositions and methods useful for hcv infectionKWONG ANN·Filed 2012·Application pending·0 cites
- 1849US8501450B2Hepatitis C virus variantsLIN CHAO·Filed 2010·Granted Aug 6, 2013·0 cites·13 claims
- 1947US2010189688A1Dose forms comprising VX-950 and their dosage regimenVERTEX PHARMA·Filed 2009·Application pending·0 cites
- 2047US2005120398A1Animal model for HCV infectionVERTEX PHARMA·Filed 2004·Application pending·0 cites
- 2147US2012088904A1Analysis of hcv genotypesBARTELS DOUGLAS JOHN·Filed 2011·Application pending·0 cites
- 2245US2022365070A1Compositions, systems, and methods for identifying a compound that modulates one or more characteristics associated with a rbm20 condensate and/or a rbm20 polypeptideDEWPOINT THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2345US2014050697A1Analysis of hcv genotypesVERTEX PHARMA·Filed 2013·Application pending·0 cites
- 2443US2012295843A1Combination therapy for the treatment of hcv infectionKWONG ANN·Filed 2012·Application pending·0 cites
- 2541US8679740B2Methods for amplifying hepatitis C virus nucleic acidsKWONG ANN DAK-YEE·Filed 2011·Granted Mar 25, 2014·0 cites·21 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →